8-K current report · filed Oct 19, 2026

Disc Medicine, Inc. (IRON) 8-K Current Report: October 19, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 7.01IRON overview

Short answer

Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Pivotal Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints.

Disc Medicine, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Pivotal Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints
  • Results cover adults and adolescents with erythropoietic protoporphyria, supporting regulatory advancement
  • Positive pivotal data materially strengthen bitopertin’s commercialization prospects in EPP
  • Full trial results and supporting details in Exhibit 99.1

Item 8.01 · Other Events

  • APOLLO Phase 3 met all primary and secondary endpoints in 183 EPP/XLP patients, materially de-risking bitopertin’s efficacy profile
  • PPIX reduced 41.4% versus placebo, while monthly pain-free light exposure increased 12.2 hours, both statistically significant
  • Phototoxic reactions, cumulative pain-free light exposure and patient-reported quality of life all improved versus placebo
  • Dizziness affected 50% of bitopertin patients, generally mild or moderate and transient, with no adverse events above Grade 3
  • NDA resubmission planned by end-2026, with FDA decision anticipated by mid-2027, creating key regulatory catalysts and execution risk

Item EX-99.1 · Exhibit EX-99.1

  • APOLLO met both co-primary endpoints, reducing PPIX 41.4% versus placebo and adding 12.2 monthly pain-free light hours
  • All secondary endpoints statistically significant, including fewer phototoxic reactions and greater cumulative light tolerance
  • Quality-of-life measures improved significantly, with PGIC and PGIS both p<0.0001
  • Safety profile supportive, dizziness most common at 50%, generally mild or moderate and transient
  • NDA resubmission planned by end-2026, with FDA decision anticipated by mid-2027

Item EX-99.2 · Exhibit EX-99.2

  • APOLLO met both co-primary and all secondary endpoints, materially strengthening bitopertin’s case for EPP approval
  • PPIX fell 41.4% versus placebo, while month-six pain-free light exposure increased 12.2 hours
  • Phototoxic reaction incidence declined 71% versus placebo, with time to prodrome improving 56 minutes
  • Safety remained favorable, though dizziness affected 50% on bitopertin versus 11% on placebo
  • NDA resubmission planned by end-2026, with FDA decision anticipated by mid-2027 and $2B+ US addressable market cited

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Disc Medicine, Inc. 8-K filings

Get the next IRON 8-K as it lands

Follow IRON for push alerts, or ask the research agent what this filing means.